Advertisement
Wednesday, May 18, 2022
Outlook.com
Outlook.com

FDA Has Rejected Covaxin’s Emergency Use In America; Here’s Why

Ocugen in a statement on Thursday announced that as recommended by the FDA, it will pursue submission of a biologics license application (BLA) for Covaxin.

FDA Has Rejected Covaxin’s Emergency Use In America; Here’s Why
The development may delay the Covaxin launch in the US. | Representational image
FDA Has Rejected Covaxin’s Emergency Use In America; Here’s Why
outlookindia.com
2021-06-11T14:16:28+05:30

In a big jolt to Bharat Biotech, the US Food and Drug Administration on Friday rejected its proposal for an emergency use authorization (EUA) of its Covid-19 vaccine Covaxin.

The drug regulator has “recommended” Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data instead of EUA (Emergency Use Authorisation) application for its vaccine candidate. According to a  statement issued Thursday, the biopharmaceutical company, which has inked a deal with Bharat Biotech for the supply of Covaxin to the US said that it will pursue submission of a biologics license application (BLA) for Covaxin as recommended by the FDA. Notably, BLA is a “full approval” mechanism by the FDA for drugs and vaccines.

“The company will no longer pursue an Emergency Use Authorization (EUA) for Covaxin. The FDA provided feedback to Ocugen regarding the Master File. The company had previously submitted and recommended that Ocugen pursue a BLA submission instead of a EUA application for its vaccine candidate and requested additional information and data,” Ocugen said.

The development may delay the Covaxin launch in the US. “Although we were close to finalising our EUA application for submission, we received a recommendation from the FDA to pursue a BLA path. While this will extend our timelines, we are committed to bringing Covaxin to the US,” Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and co-founder of Ocugen said. 

He added, “This differentiated vaccine is a critical tool to include in our national arsenal given its potential to address the SARS-CoV-2 variants, including the delta variant, and given the unknowns about what will be needed to protect US population in the long term.”

The rejection of emergency authorization was large because the company (Occugen) submitted partial data from the Covaxin trial only in March this year, but the USFDA had issued a revised guideline for covid vaccine approval last month that said it will no longer grant emergency authorization to new applications.

Ocugen in a statement provided the reason for the FDA’s rejection of Covaxin’s emergency use. “The FDA provided feedback to Ocugen regarding the Master File the Company had previously submitted and recommended that Ocugen pursue a BLA submission instead of a EUA application for its vaccine candidate and requested additional information and data,” Ocugen informed NYSE in a statement.

With PTI inputs

Advertisement

Outlook Newsletters

Advertisement
Advertisement
Advertisement

Read More from Outlook

Lament Of Separation: Songs Of Habba Khatun, Last Queen Of Kashmir, Still Echo In Valley

Lament Of Separation: Songs Of Habba Khatun, Last Queen Of Kashmir, Still Echo In Valley

In happy times and sad, Habba Khatun’s sensuous songs make both young and old emotional. With the never-ending conflict bringing tragedies to every doorstep, Habba’s lyrics of separation amplify their mourning.

How Indian Laws Govern People’s Right To Love And Live

How Indian Laws Govern People’s Right To Love And Live

In India, only those relationships between a man and a woman are considered to be legitimate when there is a marriage between the two.

Kohli Quits Test Captaincy, Leaves Leadership Vacuum

Kohli Quits Test Captaincy, Leaves Leadership Vacuum

Virat Kohli, 33, had recently stepped down as India's T20I captain and was subsequently removed as the ODI captain.

UP Elections 2022: How Congress Is Harnessing Power Of 'Persecuted' Women To Counter BJP

UP Elections 2022: How Congress Is Harnessing Power Of 'Persecuted' Women To Counter BJP

A Mahila Congress leader, who is the face of the ‘Ladki Hoon, Lad Sakti Hoon’ campaign, however, has accused the party of anti-women bias after she was denied a ticket.

Advertisement